An unexpected effect of chronic treatment with Temozolomide in patients with metastatic, well-differentiated neuroendocrine tumors

#3128

Introduction: Temozolomide (TEM) is an alkylating agent indicated for several neoplasms treatment, as neuroendocrine tumors (NETs). Myelosuppression is the most common adverse event (AE).

Aim(s): We reported a never described before AE to TEM in a case series of NETs patients (pts).

Materials and methods: We reviewed clinical records of NET pts treated with TEM at our institute between 2018 and 2020. We collected clinical, biochemical and radiologic data about this AE.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Laffi A, Nicosia L, Spada F, Rubino M, Fazio N,

Keywords: NET, neuroendocrine, temozolomide, gynecomastia, breast,